Zai Lab Ltd
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
ZLAB$26.43-1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 31, 202 and
Consolidated Balance Sheets
(in thousands of U.S. dollars (“$”), except for number of shares and per share data)
| December 31, | |||
|---|---|---|---|
| Notes | 2023 | 2022 | |
| Assets | |||
| Current assets | |||
| Cash and cash equivalents | 3 | 790,151 | 1,008,470 |
| Short-term investments | 5 | 16,300 | — |
| Accounts receivable (net of allowance for credit loss of $17 and $11 as of December 31, 2023 and 2022, respectively) | 59,199 | 39,963 | |
| Notes receivable | 6,134 | 8,608 | |
| Inventories, net | 6 | 44,827 | 31,621 |
| Prepayments and other current assets | 22,995 | 35,674 | |
| Total current assets | 939,606 | 1,124,336 | |
| Restricted cash, non-current | 4 | 1,113 | 803 |
| Long-term investments | 7 | 9,220 | 6,431 |
| Prepayments for equipment | 111 | 1,396 | |
| Property and equipment, net | 8 | 53,734 | 57,863 |
| Operating lease right-of-use assets | 9 | 14,844 | 19,512 |
| Land use rights, net | 3,069 | 6,892 | |
| Intangible assets, net | 13,389 | 1,511 | |
| Long-term deposits | 1,209 | 1,396 | |
| Total assets | 1,036,295 | 1,220,140 | |
| Liabilities and shareholders’ equity | |||
| Current liabilities | |||
| Accounts payable | 112,991 | 65,974 | |
| Current operating lease liabilities | 9 | 7,104 | 7,050 |
| Other current liabilities | 12 | 82,972 | 66,818 |
| Total current liabilities | 203,067 | 139,842 | |
| Deferred income | 28,738 | 21,360 | |
| Non-current operating lease liabilities | 9 | 8,047 | 13,343 |
| Other non-current liabilities | 325 | — | |
| Total liabilities | 240,177 | 174,545 | |
| Commitments and contingencies (Note 20) | |||
| Shareholders’ equity | |||
| Ordinary shares (par value of $0.000006 per share; 5,000,000,000 shares authorized, 977,151,270 and 962,455,850 shares issued as of December 31, 2023 and 2022, respectively; 972,239,070 and 960,219,570 shares issued and outstanding as of December 31, 2023 and 2022, respectively) | 6 | 6 | |
| Additional paid-in capital | 2,975,302 | 2,893,120 | |
| Accumulated deficit | (2,195,980) | (1,861,360) | |
| Accumulated other comprehensive income | 37,626 | 25,685 | |
| Treasury stock (at cost, 4,912,200 and 2,236,280 shares as of December 31, 2023 and 2022, respectively) | (20,836) | (11,856) | |
| Total shareholders’ equity | 796,118 | 1,045,595 | |
| Total liabilities and shareholders’ equity | 1,036,295 | 1,220,140 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.